Please assess the completion status of the following clinical trial:

Trial Title: Perifosine in Treating Patients With Recurrent Prostate Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients must have histologically or cytologically confirmed adenocarcinoma of the prostate~* Patients must have a rising PSA \>= 2.0 following a nadir after local curative therapy (either radical prostatectomy and/or pelvic radiation) with no clinical or radiographic evidence of metastatic disease; PSA \>= 2.0 elevation must be confirmed by two consecutive increases, each measured at least 2 weeks apart; only patients with a biochemical (PSA) recurrence with no physical exam or radiographic evidence of local or distant relapse are eligible~* Prior hormonal therapy in the form of neoadjuvant or adjuvant therapy is allowed as long as neither lasted for more than 9 months; androgen deprivation therapy must have been completed at least one year prior to registration; patients could not have had a rising PSA at the time that neoadjuvant or adjuvant therapy was stopped~* Life expectancy of greater than 3 months~* Karnofsky performance status \> 60%~* Leukocytes \>= 3,000/uL~* Absolute neutrophil count \>= 1,500/uL~* Platelets \>= 100,00/uL~* Total bilirubin =\< 1.5 mg/dL~* AST (SGOT)/ALT (SGPT) =\< 2.5 x institutional upper limit of normal~* Creatinine within normal institutional limits OR creatinine clearance \>= 60 mL/min~* Computed tomography scan or MRI of the pelvis negative for metastatic disease within 3 months prior to registration~* Bone scan negative for metastatic disease within 3 months prior to registration~* Chest PA and lateral films negative for metastatic disease within 3 months prior to registration~* Prior vaccine therapy is allowed if completed at least 6 months prior to registration~* Men enrolled in this trial must agree to use adequate contraception prior to study entry and for the duration of study participation~* Ability to understand and the willingness to sign a written informed consent document~Exclusion Criteria:~* Patients who have had any prior cytotoxic chemotherapy~* Patients may not be receiving any other investigational agents~* Patients receiving concurrent chemotherapeutic agents, biological response modifiers, radiation therapy, corticosteroid or hormonal therapy; no complementary or alternative therapy (e.g., St. John's Wort, PC-SPES, or any other herbal remedies taken for the purpose of treating prostate cancer) may be given during protocol treatment~* History of allergic reactions attributed to compounds of similar chemical or biologic composition to perifosine~* Androgen deprivation given for reasons other than neoadjuvant or adjuvant therapy~* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements~* HIV-positive patients receiving combination anti-retroviral therapy are excluded from the study because of possible pharmacokinetic interactions with perifosine; appropriate studies will be undertaken in patients receiving combination anti-retroviral therapy when indicated~* No prior malignancy is allowed except for the following: adequately treated basal cell or squamous cell skin cancer, in situ carcinoma of any site, adequately treated stage I or II cancer from which the patient is currently in complete remission, or any other cancer from which the patient has been disease-free for 5 years

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment (perifosine) (Type: EXPERIMENTAL): Patients receive oral perifosine once daily on days 1-28. On day 1 of course 1 only, patients receive 2 doses of oral perifosine. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients with progressive disease by PSA alone may receive up to 3 additional courses of therapy after documentation of progression.

Based on this trial design, predict the completion outcome and termination type (if applicable).